| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/28/2009 | WO2009065854A1 N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors |
| 05/28/2009 | WO2009065850A1 N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors |
| 05/28/2009 | WO2009065846A1 A method for treating addiction |
| 05/28/2009 | WO2009065596A2 Use of mnk inhibitors for the treatment of alzheimer's disease |
| 05/28/2009 | WO2009065169A1 Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof |
| 05/28/2009 | WO2009047723A3 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders |
| 05/28/2009 | WO2009046880A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009046877A3 Use of a histrelin and leuprolide as therapeutic agents |
| 05/28/2009 | WO2009046822A3 Use of the peptide ymdgtmsqv as a therapeutic agent |
| 05/28/2009 | WO2009045313A3 Oxypiperidine derivatives as histamine receptor antagonists |
| 05/28/2009 | WO2009043527A3 Therapeutic use of human growth hormone 1-43 |
| 05/28/2009 | WO2009043521A3 Use of urocortin iii and urocortin i as therapeutic agents |
| 05/28/2009 | WO2009043506A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009043456A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009040051A3 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
| 05/28/2009 | WO2009040023A3 Use of galnon as a therapeutic agent |
| 05/28/2009 | WO2009040005A3 Use of the peptide rfmwmr as a therapeutic agent |
| 05/28/2009 | WO2009039985A3 Therapeutic uses of urocortin ii |
| 05/28/2009 | WO2009039984A3 Therapeutic uses of urocortin ii and kisspeptin ( 27-54 ) |
| 05/28/2009 | WO2009039983A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009039978A3 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof |
| 05/28/2009 | WO2009033747A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009033660A3 Use of octreotide as a therapeutic agent |
| 05/28/2009 | WO2009027105A3 Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
| 05/28/2009 | WO2009026657A8 Flavonoid ppar agonists |
| 05/28/2009 | WO2009024324A9 Treatment of sleep disorders |
| 05/28/2009 | WO2008152086A3 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators |
| 05/28/2009 | WO2008112162A3 Compositions and methods for treating diseases, disorders or conditions characterized by myelin degeneration, myelin deficiency or loss |
| 05/28/2009 | WO2008071960A3 Methods of increasing neurogenesis |
| 05/28/2009 | US20090137834 Levodopa prodrugs, and compositions and uses thereof |
| 05/28/2009 | US20090137677 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137676 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137674 Administering L-lysine-d-amphetamine or salts |
| 05/28/2009 | US20090137673 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137672 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137665 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase |
| 05/28/2009 | US20090137660 Cytokine Modulators Using Cyclic Glycerides of Essential Polyunsaturated Fatty Acids |
| 05/28/2009 | US20090137655 Non-Steroidal Ligands for the Glucocorticoid Receptor, Compositions and Uses Thereof |
| 05/28/2009 | US20090137653 Substituted benzylamines as cyp2a inhibitors and uses thereof to treat nicotine dependence |
| 05/28/2009 | US20090137652 Methods for neuroprotection |
| 05/28/2009 | US20090137650 New Compounds |
| 05/28/2009 | US20090137643 Methods for Inhibiting or Reversing Tau Filament Fibrillization |
| 05/28/2009 | US20090137642 2-Acylaminothiazole Derivatives |
| 05/28/2009 | US20090137629 Sigma receptor binding agent containing indanone derivative |
| 05/28/2009 | US20090137628 Formulations of Indanylamines and the Use Thereof as Local Anesthetics and as Medication for Chronic Pain |
| 05/28/2009 | US20090137627 Method for Treating Chronic Pain |
| 05/28/2009 | US20090137625 Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors |
| 05/28/2009 | US20090137619 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent |
| 05/28/2009 | US20090137618 Pro-drugs for controlled release of biologically active compounds |
| 05/28/2009 | US20090137612 Treatment with combined use of oxypurines and ascorbate to prevent and mitigate iron-catalized oxidative damage in Alzheimer's disease and other neurodegenerative disorders |
| 05/28/2009 | US20090137604 corticotropin releasing factor receptor antagonists such as 8-(N-butyl-N-(2-butynyl)amino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine, used for the treatment of nervous system, psychological, eating, sleep, and gastrointestinal disorders |
| 05/28/2009 | US20090137598 Method of treating metabolic disorders and depression with dopamine receptor agonists |
| 05/28/2009 | US20090137594 Pentafluorosulphanyl-Substituted Compound And Its Use For Producing Medicaments |
| 05/28/2009 | US20090137587 4-[(4-Chlorobenzyl)oxy]-1-(4-[(1E)-3-(methylamino)-1-propen-1-yl]phenyl)pyridin-2(1H)-one; remedy for metabolic disorders such as obesity, diabetes, hormone disorder; cardiovascular disorders (stenocardia, acute or congestive heart failure); nervous system disorders (bulimia, anxiety, epilepsy etc.) |
| 05/28/2009 | US20090137584 Sulfonyl benzimidazole derivatives |
| 05/28/2009 | US20090137577 Heterocyclic compounds |
| 05/28/2009 | US20090137576 Novel Piperidine Derivative |
| 05/28/2009 | US20090137575 Fused Tetracyclic mGluR1 Antagonists as Therapeutic Agents |
| 05/28/2009 | US20090137573 1,3-Disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their Use in Medicaments |
| 05/28/2009 | US20090137571 2-Cyclopentyl-N-(2-bromo-6-trifluoromethyl-4-(thio)morpholin-4-yl-phenyl)-acetamide;potent openers of the KCNQ family of potassium ion channels; antiepileptic agents;anticonvulsants; anxiolytic agents; neurodegenerative disorders; analgesics for headaches, neuropathic pain; bipolar disorders |
| 05/28/2009 | US20090137565 Method for treatment of movement disorders |
| 05/28/2009 | US20090137563 Process for the prepartion of olanzapine |
| 05/28/2009 | US20090137562 Substituted benzyl amine compounds |
| 05/28/2009 | US20090137560 Imidazole compounds having pharmaceutical activity towards the sigma receptor |
| 05/28/2009 | US20090137555 activity of CDK1, CDK2, CDK4, CDK5, GSK3 beta , Bcr-ab1, Flt-3, c-Kit, PDGFR beta , Src, Mek1 and CK1; 2-[N'-(2,3-dibromo-8-oxo-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-c]azepin-4-ylidene)-hydrazino]-benzoic acid; antiinflammatory agent; autoimmune, neurological, cardiovasculal, hormone-related diseases |
| 05/28/2009 | US20090137540 Compositions for the treatment of gastrointestinal inflammation |
| 05/28/2009 | US20090137530 Amine Compound and Use Thereof for Medical Purposes |
| 05/28/2009 | US20090137515 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137513 RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 05/28/2009 | US20090137512 nucleotide sequence complementary to a target RNA sequence and a second sequence chemically modified so it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; cancer, proliferative diseases |
| 05/28/2009 | US20090137511 RNA INTERFERENCE MEDIATED INHIBITION OF PLACENTAL GROWTH FACTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137509 RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137508 Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability |
| 05/28/2009 | US20090137491 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137489 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137488 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137487 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137486 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137483 Antagonists of the bradykinin B1 receptor |
| 05/28/2009 | US20090137476 Apo-2 ligand variants and uses thereof |
| 05/28/2009 | US20090137471 Ngf variants |
| 05/28/2009 | US20090137461 Abuse-resistant amphetamine prodrugs |
| 05/28/2009 | US20090137040 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| 05/28/2009 | US20090136970 Nogo receptor homologues and their use |
| 05/28/2009 | US20090136573 Methods for Making and Delivering Rho-Antagonist Tissue Adhesive Formulations to the Injured Mammalian Central and Peripheral Nervous Systems and uses Thereof |
| 05/28/2009 | US20090136565 Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R |
| 05/28/2009 | US20090136552 Growth factors nsg28, nsg30, and nsg32 |
| 05/28/2009 | US20090136549 Transdermal patch containing rasagiline for treatment or prophylaxis of nervous system disease and its preparation process |
| 05/28/2009 | US20090136506 Conserved Membrane Activator of Calcineurin (CMAC), a Novel Therapeutic Protein and Target |
| 05/28/2009 | US20090136463 Schwann Cell Bridge Implants and Phosphodiesterase Inhibitors to Stimulate CNS Nerve Regeneration |
| 05/28/2009 | US20090136461 Neuronal differentiation method of adult stem cells using small molecules |
| 05/28/2009 | US20090136457 Methods of treating spinal cord injury and minimizing scarring |
| 05/28/2009 | US20090136456 Methods of treating neurodegenerative disorders |
| 05/28/2009 | US20090136453 Methods for treating pain |
| 05/28/2009 | US20090136450 Therapy for neurological diseases |
| 05/28/2009 | DE19681420B4 Vorrichtung und Bereitstellungsverfahren für eine transdermale Elektrotransport-Abgabe von Fentanyl und Sufentanil Apparatus and method for providing a transdermal electrotransport delivery of fentanyl and sufentanil |
| 05/28/2009 | CA2706586A1 Novel compounds as cannabinoid receptor ligands and uses thereof |
| 05/28/2009 | CA2706328A1 Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor |
| 05/28/2009 | CA2706203A1 Use of mnk inhibitors for the treatment of alzheimer's disease |
| 05/28/2009 | CA2705965A1 External preparation composition comprising fatty acid-based ionic liquid as active ingredient |